GSA Capital Partners LLP Acquires 18,616 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

GSA Capital Partners LLP raised its holdings in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 129.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,979 shares of the company’s stock after purchasing an additional 18,616 shares during the period. GSA Capital Partners LLP owned 0.06% of EyePoint Pharmaceuticals worth $264,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of EYPT. Greenwich Wealth Management LLC raised its holdings in EyePoint Pharmaceuticals by 8.3% in the 3rd quarter. Greenwich Wealth Management LLC now owns 11,700 shares of the company’s stock worth $93,000 after purchasing an additional 900 shares in the last quarter. Arizona State Retirement System increased its position in shares of EyePoint Pharmaceuticals by 9.7% during the second quarter. Arizona State Retirement System now owns 13,251 shares of the company’s stock valued at $115,000 after buying an additional 1,171 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in EyePoint Pharmaceuticals by 68.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,293 shares of the company’s stock worth $82,000 after buying an additional 4,172 shares in the last quarter. American International Group Inc. raised its stake in EyePoint Pharmaceuticals by 38.4% in the first quarter. American International Group Inc. now owns 18,378 shares of the company’s stock worth $380,000 after buying an additional 5,101 shares in the last quarter. Finally, Fiera Capital Corp lifted its holdings in EyePoint Pharmaceuticals by 0.9% in the second quarter. Fiera Capital Corp now owns 677,038 shares of the company’s stock worth $5,890,000 after buying an additional 5,920 shares during the period. Hedge funds and other institutional investors own 99.41% of the company’s stock.

Wall Street Analysts Forecast Growth

EYPT has been the topic of several research reports. Robert W. Baird dropped their price target on EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating on the stock in a research report on Monday, November 11th. JPMorgan Chase & Co. dropped their target price on shares of EyePoint Pharmaceuticals from $32.00 to $29.00 and set an “overweight” rating on the stock in a report on Tuesday, August 13th. Scotiabank assumed coverage on shares of EyePoint Pharmaceuticals in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $18.00 price target for the company. Chardan Capital lifted their price target on shares of EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Finally, StockNews.com upgraded shares of EyePoint Pharmaceuticals to a “sell” rating in a report on Saturday, September 21st. One equities research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company. According to MarketBeat.com, EyePoint Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $28.00.

EyePoint Pharmaceuticals Stock Performance

Shares of EyePoint Pharmaceuticals stock opened at $8.95 on Friday. The company has a 50-day simple moving average of $9.77 and a two-hundred day simple moving average of $9.54. The stock has a market capitalization of $610.84 million, a PE ratio of -4.48 and a beta of 1.50. EyePoint Pharmaceuticals, Inc. has a 52-week low of $5.86 and a 52-week high of $30.99.

EyePoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.